Marey Hatem M, Elmazar Hesham F, Mandour Sameh S, Khairy Hany A
J Pediatr Ophthalmol Strabismus. 2018 Jan 1;55(1):37-42. doi: 10.3928/01913913-20170703-12. Epub 2017 Oct 9.
To evaluate the safety and efficacy of combined oral and topical beta blockers for the treatment of superficial periocular infantile hemangioma at the early proliferative stage.
This was a randomized, controlled comparison trial involving 25 patients. Patients were randomly enrolled into two groups: the topical and systemic treatment and systemic treatment only groups. The topical and systemic treatment group was treated with oral propranolol (1 mg/kg per day initially, increased to 2 mg/kg per day gradually in 2 weeks) and timolol maleate 0.5% gel. The systemic treatment only group received oral propranolol (1 mg/kg per day initially, increased to 2 mg/kg per day gradually in 2 weeks) and simple eye ointment to be applied to the lesion. The Hemangioma Activity Score was used to record the proliferative activity of the hemangioma. The main outcomes of the study were the change in the hemangioma size, the proliferative activity, and the treatment side effects.
At the end of the treatment period, the Hemangioma Activity Score was significantly improved in both groups from their values before treatment. However, the score obtained after treatment was significantly better in the topical and systemic treatment group (P < .05). Regarding the response to treatment, 10 and 3 cases in the topical and systemic treatment and systemic treatment only groups, respectively, showed a good response, with a significant difference between the two groups (P < .50). There were no recorded serious local or systemic complications during treatment in either group.
The results from combining topical with oral beta blockers showed that topical beta blockers are of additive value in treating superficial periocular infantile hemangioma in the early proliferative stage. [J Pediatr Ophthalmol Strabismus. 2018;55(1):37-42.].
评估口服与局部应用β受体阻滞剂联合治疗早期增殖期浅表性眶周婴儿血管瘤的安全性和有效性。
这是一项随机对照比较试验,涉及25例患者。患者被随机分为两组:局部及全身治疗组和仅全身治疗组。局部及全身治疗组接受口服普萘洛尔(初始剂量为每日1mg/kg,2周内逐渐增至每日2mg/kg)和0.5%马来酸噻吗洛尔凝胶治疗。仅全身治疗组接受口服普萘洛尔(初始剂量为每日1mg/kg,2周内逐渐增至每日2mg/kg)和用于病变部位的单纯眼膏治疗。采用血管瘤活动评分记录血管瘤的增殖活性。该研究的主要结局指标为血管瘤大小的变化、增殖活性及治疗副作用。
在治疗期末,两组的血管瘤活动评分均较治疗前显著改善。然而,局部及全身治疗组治疗后的评分显著更好(P <.05)。关于治疗反应,局部及全身治疗组和仅全身治疗组分别有10例和3例显示出良好反应,两组间差异有统计学意义(P <.50)。两组在治疗期间均未记录到严重的局部或全身并发症。
局部与口服β受体阻滞剂联合应用的结果表明,局部应用β受体阻滞剂在治疗早期增殖期浅表性眶周婴儿血管瘤方面具有附加价值。[《小儿眼科与斜视杂志》。2018;55(1):37 - 42。]